VAMP2 correlates to duration of dementia by Vallortigara, Julie et al.
1 
Decreased Levels of VAMP2 and Monomeric Alpha-Synuclein Correlate with Duration of 
Dementia 
 
Julie Vallortigara
1
, David Whitfield
1*
, William Quelch
1
, Amani Alghamdi
1
, David Howlett
1
, 
Tibor Hortobágyi
2
, Mary Johnson
3
, Johannes Attems
3
, John T. O’Brien3, 4, Alan Thomas3, Clive 
G. Ballard
1
, Dag Aarsland
5, 6
, Paul T. Francis
1
 
 
1
Wolfson Centre for Age-Related Diseases, Institute of Psychiatry, Psychology and 
Neuroscience, King’s College London, London, UK 
2
Division of Neuropathology, Institute of Pathology, Faculty of Medicine, University of 
Debrecen, Debrecen, Hungary 
3
Institute of Neuroscience, Newcastle University, CAV, Newcastle upon Tyne, UK 
4
Department of Psychiatry, University of Cambridge, Cambridge, UK 
5
Department of Neurobiology, Ward Sciences and Society, Karolinska Institute, Stockholm, 
Sweden 
6
Centre for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway 
 
Running title: VAMP2 correlates to duration of dementia 
Accepted 8 October 2015 
 
*Correspondence to: Dr. David Whitfield, Wolfson Centre for Age Related Diseases, King’s 
College London, SE1 1UL, UK. Tel.: +44 02078486910; E-mail: david.r.whitfield@kcl.ac.uk   
2 
ABSTRACT 
 Alpha-synuclein (α-syn) aggregations are the key pathological hallmark of dementia with 
Lewy bodies (DLB) and Parkinson’s disease dementia (PDD), but are also frequently present in 
Alzheimer’s disease (AD). Much remains unknown about the role of α-syn in the synapse and 
the wider role of synaptic dysfunction in these dementias. Changes in concentrations of key 
‘SNAP (Soluble N-ethylmaleimide Sensitive Factor Attachment Protein) Receptor’ (SNARE) 
proteins as a consequence of alterations in the aggregation state of α-syn may contribute to 
synaptic dysfunction in patients with DLB, PDD, and AD and result in impaired cognition. We 
have studied a large cohort (n=130) of autopsy confirmed DLB, PDD, AD, and control brains. 
Using semi-quantitative western blotting, we have demonstrated significant changes across the 
diagnostic groups of DLB, PDD, and AD in the SNARE and vesicle proteins syntaxin, Munc18, 
VAMP2, and monomeric α-syn in the prefrontal cortex, with a significant reduction of Munc18 
in AD patients (p<0.001). This correlated to the final MMSE score before death (p=0.016). We 
also identified a significant negative correlation between the duration of dementia and the levels 
of the binding partners VAMP2 (p=0.0004) and monomeric α-syn (p=0.0002). Our findings may 
indicate that an upregulation of SNARE complex related proteins occurs in the early stages of 
disease as an attempt at compensating for failing synapses, prior to widespread deposition of 
pathological α-syn.  
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INTRODUCTION 
 Dementia is defined as progressive cognitive decline of sufficient magnitude to interfere with 
normal social or occupational function. Alzheimer’s disease (AD) and the Lewy body dementias 
(LBD), incorporating dementia with Lewy bodies (DLB) and Parkinson’s disease dementia 
(PDD), collectively comprise over 70% of all dementia diagnoses 
(http://www.alzheimers.org.uk). LBD is pathologically characterized by α-synuclein (α-syn), 
with varying amounts of amyloid-β protein (Aβ) and hyperphosphorylated microtubule 
associated protein tau (tau) aggregates in addition to synaptic loss [1]. Clinical hallmarks include 
fluctuating and deteriorating cognition, hallucinations, and parkinsonism [2, 3]. AD is 
characterized by Aβ and tau aggregates and gradual worsening of cognition, in particular 
episodic memory and executive function [4, 5]. 
 α-Syn, first identified as the main component of Lewy bodies (LBs) [6]—and thus the key 
pathological protein of DLB and PDD—is, under physiological conditions, located in the 
presynaptic terminal. Kramer and Schulz-Schaeffer [7] reported accumulation of small 
aggregates of α-syn at the synapses of DLB postmortem brains. These aggregates were proposed 
to interfere with synaptic function. The authors also suggested that the formation of small 
aggregates of α-syn was a direct precursor to the development of LBs, and possibly represented a 
final cytoprotective attempt before cell death. Thus, focus on the events occurring at the synapse 
in advance of LB formation could be of greater potential therapeutic benefit. This is of relevance 
not just to the established synucleinopathies such as DLB and PDD but also AD. It is now 
recognized that a proportion of sporadic AD cases present with LBs; this has been reported to be 
as high as 51% [8], and is particularly observed within the amygdala where LBs are often co-
localized with neurofibrillary tangles [9-11]. 
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 Some of the mutations in the SNCA gene known to give rise to α-syn disorders exert their 
pathogenic effect through promotion of aggregation or oligomerization of α-syn [12]. In addition 
to involvement in pathogenic mechanisms, there has been increasing focus on the physiological 
role of α-syn. Current understanding indicates that α-syn plays a role in neurotransmitter release, 
synaptic plasticity, and pre-synaptic vesicle pool size [13-15]. More particularly it is thought that 
monomeric α-syn drives formation of the SNARE complex through a chaperone-like activity 
involving binding to phospholipids and VAMP2 (vesicle-associated membrane protein 2, or 
synaptobrevin-2) [16]. SNARE is an acronym for ‘SNAP (Soluble N-ethylmaleimide Sensitive 
Factor Attachment Protein) Receptor’. SNARE proteins play a key role in neurotransmitter-
containing vesicle fusion to the presynaptic membrane thereby modulating neurotransmitter 
release [17]. Interestingly, it was recently reported that large α-syn oligomers bind preferentially 
to VAMP2 (vesicle-associated membrane protein 2), resulting in inhibition of docking between 
donor and acceptor vesicles [18]. Thus it is plausible that VAMP2 could represent a key 
component for mediating the impact of α-syn. 
 VAMP2 and syntaxin 1, both members of the SNARE protein family, are respectively 
localized to synaptic vesicles and the presynaptic membrane where they form part of the SNARE 
complex required for vesicle release (see Figure 1) [17]. Munc18 binds to syntaxin 1, and is 
thought to assist in the first steps of SNARE assembly, as well as playing a role in later stages of 
the exocytosis [19-21]. Reductions in SNARE proteins have been previously reported in LBD 
and AD. Specifically, it was found that levels of synaptophysin, syntaxin, and SNAP25 were 
decreased in individuals with DLB in the visual areas (BA17 and BA18/19) [22]. Furthermore, 
we have reported reductions of dynamin1, a regulator of synaptic vesicle recycling, to be 
associated with cognitive decline in LBD [23]. It has also been demonstrated that the same 
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SNARE proteins can be elevated in AD during the mild stages of dementia, but decline as the 
severity of disease develops [24]. It would appear that synaptic changes can vary by neocortical 
region and pathology. Thus, it is apparent that much about the synaptic changes in AD and LBD 
remains to be elucidated.  
 This study aims to aid our understanding of the synaptic dysfunction that occurs in LBD and 
AD by providing a characterization of changes in key markers of the synapse machinery and any 
relationships to other aspects of the disease. We therefore determined the expression of the 
presynaptic proteins α-syn, VAMP2, syntaxin1A, Munc18, and the ubiquitous synaptic marker 
synaptophysin (SPP) and investigated the relationships between these proteins and clinical and 
pathological hallmarks of the disease. 
 
MATERIALS AND METHODS 
Participants, diagnosis, and assessment 
 Table 1 shows the demographic details of the patients and controls. Postmortem brain tissue 
was kindly supplied by the following Brains for Dementia Research Network brain banks: the 
MRC London Neurodegenerative Diseases Brain Bank, the Thomas Willis Oxford Brain 
Collection and the Newcastle Brain Tissue Resource, and from the University Hospital 
Stavanger (Norway). Informed consent was obtained for all tissue to be used in research and the 
study had ethics approval (08/H1010/4). Prefrontal cortex (Brodmann area, BA9) was used for 
all biochemical and histopathological analysis. BA9 was selected due to its proposed role in 
executive function and cognition [25], decline of which is a cardinal symptom of DLB and PDD,  
Neuropathological assessment was performed according to standardized neuropathological 
scoring/grading systems, including Braak staging, Consortium to Establish a Registry for 
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Alzheimer’s Disease (CERAD) scores, Newcastle/ McKeith Criteria for LBD, National Institute 
on Aging-Alzheimer’s Association (NIA-AA) guidelines and phases of amyloid-β (Aβ) 
deposition (Aβ-phases) [2, 26-29]. Controls were neurologically normal, with only mild age 
associated neuropathological changes (e.g., neurofibrillary tangle Braak stage ≤II) and no history 
of neurological or psychiatric disease.  
 Cognitive impairment data consisted of the last Mini-Mental State Examination (MMSE) 
scores a maximum of two years prior to death [30]. Patients and controls were categorized as 
previously described [31]. Final diagnoses for patients are clinico-pathological consensus 
diagnoses incorporating the one-year rule to differentiate DLB and PDD [2]. 
  
Immunohistochemistry 
 Semi-quantitative assessments of Aβ, tau and α-syn pathology were conducted as in our 
previous study [32] blind to clinical diagnosis, by neuropathologists, using a scale of 0 (none), 1 
(sparse), 2 (moderate), and 3 (severe/frequent) to score sections from BA9, BA24, and BA40. 
For detection of senile Aβ plaques, sections were stained with an anti-Aβ 1E8 or 4G8 antibody at 
1:1000. Tau immunohistochemistry (AT8 antibody (Innogenetics) at 1:200) and silver 
impregnation (Gallyas or modified Bielschowsky) were used to detect neurofibrillary tangles, 
neuritic plaques, dystrophic neurites, and neuropil threads. α-syn pathology was detected using 
NCL-SYN antibody (Novocastra Laboratories) at 1:200. 
 
Preparation of tissue samples for western blotting 
 Preparation of tissue for western blotting was as previously described [33]. Briefly, grey 
matter was isolated from the tissue and homogenized in ice cold buffer containing 50 mM tris-
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HCL, 5 mM EGTA, 10 mM EDTA, ‘complete protease inhibitor cocktail tablets’ (Roche, 1 
tablet per 50ml of buffer), and 2 μg/ml pepstatin A dissolved in ethanol:DMSO 2:1 (Sigma). 
Buffer was used at a ratio of 2 ml to every 100 mg of tissue and homogenization performed using 
an IKA Ultra-Turrax mechanical probe (KIA Werke, Germany) until the liquid appeared 
homogenous. 
 Protein concentration was established using the Coomassie (Bradford) Protein Assay Kit 
(Thermo Scientific); 10 μl of crude homogenate was diluted 1:50 and read in triplicate at 595nm 
using a FlexStation 3 (Molecular Devices). A BSA standard curve run at the same time as the 
samples was used to calculate the concentration. 
 
Western blotting 
 Crude brain homogenate was diluted 4:5 with 5x sample buffer (Genscript MB01015), boiled 
for 5 min then stored at -20°C. Samples were loaded at 20 μg/ml total protein on 10% SDS-
polyacrylamide gel for protein separation, transferred to nitrocellulose membrane (Hydrobond-C, 
Amersham), and probed with either anti-Syntaxin1 (abcam ab24731, 1:20000), anti-Munc18 
(abcam ab75042, 1:2000), anti-VAMP2 (abcam ab70222, 1:10000), anti-alpha-synuclein 
monomeric (BD Transduction Laboratories 610787, 1:20000) or anti-synaptophysin (abcam 
ab8049, 1:10000), and the relevant secondary antibody (IRDye from LI-COR). Bands were 
detected using an Odyssey infrared fluorescent scanner, and in all cases a single band was 
observed at the correct molecular weight (see Figure 2). The integral of intensity was quantified 
using Odyssey infrared imaging systems application software version 3.0.16 and expressed as 
ratios to rat cortex in arbitrary units. The same rat cortex was used for all membranes to provide 
an inter-membrane control. Samples were loaded randomly so that samples from different 
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diagnostic groups were run together. We did not use a loading control as we have previously 
shown changes in the levels of beta-III-tubulin, a standard loading control, between diagnostic 
groups, and unpublished data for histone 3 showed similar variation [31]. Given the context of 
severe neurodegeneration and end stage pathology this is unsurprising and explains our decision 
not to use a loading control. 
 
Statistical analysis 
 Statistical analysis of the biochemical data was undertaken as described previously [31, 34]; 
briefly synaptophysin values were significantly predicted by the years in storage and so a 
residual variable was created for this protein to statistically remove this effect. This variable was 
then normalized using a log10 transformation. Munc18 and VAMP2 ratio values were 
normalized using a square root transformation. Syntaxin1 and monomeric α-syn ratio values 
were normalized using a LogE transformation. VAMP2 and monomeric α-syn ratio values were 
significantly predicted by age at death and so residual variables were created to compensate for 
this effect. VAMP2 ratio values were then normalized again using LogE. 
 
RESULTS 
 Synaptophysin (SPP) levels were significantly reduced in PDD cases compared to all other 
diagnostic groups but there was no significant difference between the levels of synaptophysin in 
control, AD, or DLB cases (data not shown). As Munc18, syntaxin1, VAMP2, and monomeric 
α-syn are all synaptic proteins and we observed the aforementioned decrease in synapses, it was 
decided to express these proteins as ratios to the synaptophysin value, case by case. This 
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established approach allows the actual change in these proteins to be removed from any general 
effect of a change in synapses [35, 36].  
With regards to the Munc18:synaptophysin ratio; there was a reduction in AD cases of 33% 
compared to DLB cases, 26% compared to PDD, and 25% compared to control cases (Figure 
1A). The significant changes in the syntaxin1:synaptophysin ratio were an increase of 28% in 
AD cases compared to PDD cases and 34% compared to control cases (Figure 1B). The ratio of 
VAMP2 to synaptophysin was significantly higher in PDD cases compared to controls by 16%, 
to DLB cases by 23%, and to AD cases by 65%. Furthermore, the ratio of VAMP2 to 
synaptophysin was significantly lower in AD cases compared to DLB cases by 34% and 
compared to controls, by 42% (Figure 1C). The ratio of monomeric α-syn to synaptophysin was 
significantly higher in PDD cases compared to controls, by 25% and to AD cases by 53%. 
Furthermore, it was significantly lower in AD cases compared to DLB cases by 38% and 
compared to controls, by 22% (Figure 1D).  
 Linear regression analysis showed the years of dementia to have a highly significant negative 
correlation with the ratios of VAMP2 to synaptophysin (Figure 3A) and monomeric α-syn to 
synaptophysin (Figure 4A) in the prefrontal cortex. Likewise, a significant positive correlation 
was found between years of parkinsonism and both the ratio of VAMP2 to synaptophysin 
(Figure 3B) and the ratio of monomeric a-syn to synaptophysin (Figure 4B) in the prefrontal 
cortex. Both of these analyses included all individuals with AD, DLB, and PDD, for whom data 
on the duration of dementia was available, but not controls. The n values for years of dementia 
for both VAMP2:SPP and α-syn:SPP were: PDD n=18, DLB=23, and AD=15. For years of 
parkinsonism, they were: PDD n=18, DLB n=20, and AD n=15.  
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 We undertook further analysis to determine whether these correlations with the ratios of 
either VAMP2 or monomeric α-syn to years of dementia or parkinsonism were driven by values 
from particular diagnostic groups. When separating cases by clinical diagnosis, the only 
significant correlation remaining was between monomeric α-syn in PDD cases and the years of 
dementia (Pearson’s r=-0.562, p=0.015 n=18). 
 The ratio of Munc18 to synaptophysin correlated with the last MMSE score prior to death 
(Pearson’s r=0.282, p=0.016, n=73); the distribution and other details of the MMSE scores for 
this cohort have been reported previously [31]. There was no correlation between MMSE scores 
(the last score prior to death or the decline per year) and any of the other protein ratios (p>0.05). 
There was also no correlation between any of the protein ratios and the semi-quantitative 
pathology scores for Aβ, tau, or α-syn (p>0.05). 
 Figure 5 shows the percentage of cases of each of the diagnostic groups that fall into each 
category of pathological score. In particular, it serves to highlight the difference in spread of α-
syn pathology between the PDD and DLB cases, with far fewer PDD cases in the moderate and 
severe categories relative to the DLB cases. 
 
DISCUSSION 
 We report that a longer duration of dementia was strongly association with a decrease in 
levels of both VAMP2 and monomeric α-syn. Furthermore VAMP2 and monomeric α-syn 
appeared to be upregulated in PDD cases, cases that in general had low levels of α-syn pathology 
compared to the DLB cases. This may indicate that an upregulation of SNARE process-related 
proteins occurs in the early stages of dementia as an attempt to compensate for failing synapses, 
prior to widespread deposition of pathological α-syn. 
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 α-syn aggregation is the pathological hallmark of DLB and PDD, appearing as LBs and 
neurites throughout the cortex, but is also present in many people with AD. While evidence is 
emerging of the physiological roles of monomeric α-syn in SNARE complex processes, less is 
known about the intermediate steps that lie between this physiological role and the final 
pathological deposition seen in the end-stages of disease. We saw a strikingly similar pattern of 
change between VAMP2 and monomeric alpha-synuclein, which is not surprising given that the 
two proteins are binding partners [16]. 
 A benefit of expressing the biochemical data as a ratio to synaptophysin is that this provides 
an index to the number of synaptic terminals and helps account for changes in synapse density 
that may cloud changes to specific synaptic proteins. Importantly, the results were not 
substantially different when this ratio was not used (data not shown). We therefore conclude that 
there was a specific loss of SNARE proteins in addition to a more general loss of synapses. This 
was particularly relevant to PDD cases that were characterized by lower SPP levels.   
 The accumulation of α-syn and SNARE proteins at synaptic nerve terminals in transgenic 
mice and in Parkinson’s disease, in conjunction with impaired dopamine release in both 
transgenic mouse brain and transfected PC12 cells, is suggested by Garcia-Reitbock and 
colleagues to indicate a gain of toxic function of α-syn at the synapse [37]. This is consistent 
with previous findings in transfected cells, which showed that overexpression of α-syn inhibits 
evoked neurotransmitter release by acting at a step between vesicle docking and fusion [38]. It 
could be that a balance between monomeric α-syn and SNARE proteins is necessary for proper 
SNARE assembly and function; alternatively, it could be that an increase in α-syn causes the 
formation of toxic oligomers that affect SNARE distribution and function. This causes a problem 
as an oligomer of α-syn can bind to many VAMP2 proteins on several different vesicles causing 
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vesicle clustering [18]. By clustering around oligomeric α-syn, vesicles cannot dock at the pre-
synaptic terminal and therefore exocytosis of neurotransmitter cannot occur. 
 Here we observed a combination of increases in both monomeric α-syn and VAMP2 in PDD 
cases. A recent study reported increased expression of VAMP2 protein accompanied increased 
α-syn expression in the striatum of Snap25S187A/S187A mice [39]. These mice displayed a 
significant age-dependent change in the distribution of α-syn and its Ser129-phosphorylated form 
in hypertrophied glutamatergic nerve terminals in the striatum. Knowing that the binding of the 
C terminus of α-syn to the N terminus of VAMP2 primes the subsequent SNARE complex 
assembly [40], the increase in VAMP2 level might also reflect a compensatory response to the 
impaired synaptic vesicle release by enhancing SNARE complex formation in concert with the 
increased α-syn [39]. This increase in VAMP2 and monomeric α-syn could also relate to the 
inherent differences between PDD and the other dementias, such as the typically long period of 
parkinsonism prior to development of dementia, or to the relative lack of AD-related pathology. 
The positive correlation between MMSE prior to death and the ratio of Munc18 to synaptophysin 
underlines the importance of intact synaptic machinery to cognition. That we did not see 
correlations with the other proteins is probably due to the prefrontal cortex not being a key 
region for memory—having a stronger role in executive function, a domain the MMSE is poor at 
detecting [2]. We have previously shown that α-syn pathology in BA21 is associated with 
cognitive decline as assessed by the MMSE [32], and so it would be interesting to examine these 
SNARE proteins in this region to determine if monomeric α-syn shows a similar relationship to 
pathological α-syn. 
 In the present study, we found that a concomitant deregulation of SNARE proteins and 
monomeric α-syn was strongly associated with the duration of dementia. It has been suggested 
13 
that this process could represent an initial pathological event in DLB, eventually leading to the 
death and degeneration of neuronal cells [41]. The correlation we report between monomeric α-
syn and duration of dementia suggests this hypothesis may also apply to PDD. Alterations in 
syntaxin1 and other SNARE proteins have been previously reported in AD and DLB [21, 22, 42, 
43]; Minger et al. only found a decrease in these proteins in the oldest dementia cases and the 
Mukaetova-Ladinska studies did not separate PDD and DLB. The toxicity of α-syn, in sporadic 
and familial disease, has been proposed to arise in several ways; through inhibition of histone 
acetylation, perforation of membranes and the consequent disruption of ionic balance, and finally 
neuronal death via the inhibition of a neuronal survival factor MEF2D [44]. Beyer et al. suggest 
that in fact there maybe multiple pathways involving α-syn and other proteins linked to LBs that 
culminate in the same end-stage pathology of LBs and neurites.  
 Some limitations of this study include those that are inherent to all investigations using 
human postmortem tissue, in that we are restricted to providing observations and correlations of 
changes in what is for the most part late-stage disease. Nonetheless, it is vital to have a 
comprehensive characterization of these changes if better cell and animal models are to be 
designed that are more able to recapitulate the multiple processes underlying synaptic 
dysfunction and dementia. 
 Targeting the toxicity of α-syn at the synapse, and its connection with SNARE proteins, 
could be an effective way to tackle the pathology and the progression of the disease at an early 
stage. Further functional studies are warranted to provide insight into the chronology of the 
relationship between VAMP2 and monomeric α-syn: are changes in VAMP2 driving a loss of 
monomeric α-syn to other forms of α-syn? Or is the loss of monomeric α-syn impacting 
VAMP2, SNARE machinery, and ultimately synaptic function? Finally, development of imaging 
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ligands or an assay for cerebrospinal fluid detection of VAMP2 or monomeric α-syn would be of 
great interest given the predictive association we show between duration of dementia and 
parkinsonism, and these proteins.  
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Table 1. Summary of subjects’ demographics. Values represent means ± SEM. There were no 
significant differences (according to one-way ANOVA) between diagnostic groups for any of 
these variables. It has been demonstrated that most human brain proteins are quite stable with 
respect to postmortem factors and detailed analysis including large numbers of proteins covering 
the major cellular functions have not identified our proteins of interest as ‘at risk’ molecules 
being highly susceptible to postmortem changes [45-48]. DLB, dementia with Lewy bodies; 
PDD, Parkinson’s disease dementia; AD, Alzheimer’s disease 
 
 Control DLB PDD AD 
Number of cases 24 50 33 16 
Age of death 80.4 ± 1.4 81.7 ± 1.0 79.8 ± 1.1 88.0 ± 2.0 
Postmortem delay (h) 37.1 ± 6.4 42.9 ± 4.1 33.4 ± 2.9 34.9 ± 6.0 
Gender M/F (%) 58 / 42 56 / 44 53 / 47 31 / 69 
Brain pH 6.47 ± 0.07 6.52 ± 0.04 6.47 ± 0.06 6.30 ± 0.08 
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Figure 1. This diagram illustrates how the proteins of interest in this study interact to coordinate 
fusion of the synaptic vesicle and plasma membrane. Munc18 is bound to syntaxin-1 prior to 
vesicle docking. This allows a complex to form between VAMP2, SNAP25, and syntaxin-1, 
which results in vesicle docking. Monomeric α-syn is not shown in this diagram as its putative 
role is in stabilizing the readily releasable pool of vesicles upstream of docking [17]. 
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Figure 2. Synaptic proteins of interest expressed as a ratio to synaptophysin (SPP) and grouped 
according to clinical diagnosis. One-way ANOVA and Bonferroni post-hoc tests were used to 
determine the differences in the protein ratios between diagnostic groups. A) Munc18: n=23, 30, 
37, 16. F=(3,102) 11.995, p=0.000001. Bonferroni post-hoc tests showed AD cases to be 
significantly higher than: control p=0.001, PDD p=0.000273, and DLB p<0.000001. B) 
Syntaxin1: n=23, 31, 37, 16. F(3,103) 5.128, p=0.002. Bonferroni post-hoc tests showed AD 
cases to be significantly higher than control p=0.007 and PDD p=0.017. C) VAMP2: n=19, 24, 
29, 15. F=(3,83) 25.814, p<0.000001. Bonferroni post-hoc tests showed; PDD cases to be 
significantly higher than control p=0.01, DLB p=0.000019, and AD cases p<0.000001. 
Furthermore AD cases were significantly lower than control p=0.000004 and DLB cases 
p=0.000073. D) Mon α-syn: n=19, 24, 28, 15. F(3,82) 16.621, p<0.000001. Bonferroni PDD to 
control p=0.000463. AD to control p=0.049, PDD p<0.000001, and DLB p=0.000027. The 
vertical bars represent means with SEM.  
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Figure 3. Associations between the monomeric α-synuclein:synaptophysin (α-syn/SPP) ratio and 
the duration of dementia and parkinsonism.  
 
 
 
Linear Regression analysis showed the years of dementia and of parkinsonism to be predictors of 
the ratio of monomeric α-syn to SPP in BA9. R2=0.399. SE=0.371664. Years of dementia: B=-
25 
0.06, SE=0.015, t=-4.034, p=0.000188. Years of PD: B=0.21, SE=0.008, t=2.801, p=0.007. 
ANOVA: F=(2,50) 16.599, p=0.000003.   
26 
Figure 4. Associations between the VAMP2:synaptophysin ratio and the duration of dementia 
and parkinsonism. 
 
 
 
Linear Regression analysis showed the years of dementia and of parkinsonism to be predictors of 
the ratio of VAMP2 to SPP. R
2
=0.463. SE=0.17939. Years of dementia: B=-0.028, SE=0.007, 
t=-3.833, p=0.000355. Years of PD: B=0.15, SE=0.004, t=4.032, p=0.000189. ANOVA: 
F=(2,50) 21.595, p<0.000001.   
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Figure 5. α-synuclein pathology grouped by clinical diagnosis. 
 
The percentage of cases in each of the categories of α-synuclein pathology score (0 = absent, 1 = 
sparse, 2 = moderate, 3 = severe/frequent) according to clinical diagnosis. 
 
